The following is a summary of "Early prediction of progression-free survival of patients with locally advanced nasopharyngeal ...

Adjuvant camrelizumab significantly improves event-free survival in patients with locoregionally advanced nasopharyngeal ...

Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later in the day. Researchers observed no difference in treatment-related adverse effects ...

However, some patients relapse or present with de novo metastatic disease. For those not recently exposed to platinum-based therapies, the standard of care includes gemcitabine, cisplatin, and the ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a ...

Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...

TAIPEI (Taiwan News) — A study by Chang Gung Memorial Hospital has discovered that removing the amino acid asparagine from ...

Professor Chen Xiaozhong, one of the principal investigators of penpulimab at Zhejiang Cancer Hospital, said: "Nasopharyngeal cancer (NPC) is a highly prevalent malignancy in certain regions ...

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...